The Lotus dilemma—respond to paravalvular leakage, but not answering pacemaker implantations?

The treatment of symptomatic aortic valve stenosis has been revolutionized by transcatheter aortic valve replacement (TAVR), evolving from a last resort therapy to the standard treatment of patients at intermediate or high risk for conventional surgery (1,2).